Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2025 | $315.00 | Mkt Perform → Outperform | Raymond James |
| 11/6/2024 | $247.00 → $308.00 | Underperform → Neutral | BofA Securities |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/8/2024 | $308.00 | Mkt Perform → Outperform | Bernstein |
| 10/7/2024 | $402.00 → $261.00 | Buy → Hold | TD Cowen |
| 10/7/2024 | $519.00 → $253.00 | Buy → Hold | Jefferies |
| 10/3/2024 | $392.00 → $274.00 | Overweight → Neutral | Piper Sandler |
| 10/2/2024 | $376.00 → $247.00 | Neutral → Underperform | BofA Securities |
4 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
Program Designed to Increase Use of Recommended Medication Therapy by Connecting with Providers in Workflow LOUISVILLE, Ky. and ARLINGTON, Va., Aug. 13, 2025 /PRNewswire/ -- Humana Inc. (NYSE:HUM), one of the nation's leading health and well-being companies, and health technology pioneer DrFirst today announced the launch of a program designed to close gaps in care for patients with chronic health conditions like diabetes and cardiovascular disease while helping health care providers take timely, informed action. The first phase of this novel program aims to increase the use of statin therapy among eligible patients, aligning with a key quality metric from the Centers for Medicare & Medicaid
Reports 2Q25 earnings per share (EPS) of $4.51 on a GAAP basis, Adjusted EPS of $6.27; reports YTD EPS of $14.81 on a GAAP basis, $17.85 on an Adjusted basis 2Q25 Insurance segment benefit ratio of 89.9 percent, in line with the company's previously disclosed expectation of 'approximately 90 percent' Updates FY 2025 GAAP EPS guidance to 'approximately $13.77' from the previous estimate of 'approximately $14.68'; raises Adjusted FY 2025 EPS guidance to 'approximately $17.00', up from the previous 'approximately $16.25' guidance Raises FY 2025 consolidated revenues guidance to 'at least $128 billion' compared to the previous guidance range of $126 billion to $128 billion Affirms
New effort will expedite approvals, promote access to care, reduce administrative burdens, and enhance the patient experience Humana Inc., a leading health and well-being company, today announced accelerated efforts to approve care requests as quickly as possible and reduce the administrative burden for physicians associated with prior authorization. These actions will reduce the number of prior authorization requirements and make the process faster and more seamless, while preserving the system of checks and balances that protects patient safety by ensuring the most high-cost, high-risk treatments are reviewed and approved before care is delivered. Today's announcement builds upon the
10-Q - HUMANA INC (0000049071) (Filer)
8-K - HUMANA INC (0000049071) (Filer)
11-K - HUMANA INC (0000049071) (Filer)
Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00
BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously
KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight
4 - HUMANA INC (0000049071) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
The National Mall of Pickleball will celebrate America's most accessible sport and the game that serves all in the heart of the National Mall this September The Trust for the National Mall, Humana (NYSE:HUM), and the Humana Foundation announced today that the highly-anticipated National Mall of Pickleball is returning to America's Front Yard, the National Mall, for a third year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625316935/en/ From Friday, September 19 through Sunday, September 21, 2025, the general public can experience a weekend full of pickleball programming, activities, and community with captivating views o
Humana Inc. (NYSE:HUM), a leading health and well-being company, is expanding its commitment to senior wellness with the launch of Invite, a new campaign designed to encourage older adults of all fitness levels to stay active, connected and engaged – starting with the fastest-growing sport in America: pickleball. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618737488/en/As part of Humana's new "Invite" campaign, the health and wellness company debuted a television spot featuring senior pickleball athletes extending an open invitation to others to join the fun, stay social, and support their physical and mental well-being. A
Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So
Reports 2Q25 earnings per share (EPS) of $4.51 on a GAAP basis, Adjusted EPS of $6.27; reports YTD EPS of $14.81 on a GAAP basis, $17.85 on an Adjusted basis 2Q25 Insurance segment benefit ratio of 89.9 percent, in line with the company's previously disclosed expectation of 'approximately 90 percent' Updates FY 2025 GAAP EPS guidance to 'approximately $13.77' from the previous estimate of 'approximately $14.68'; raises Adjusted FY 2025 EPS guidance to 'approximately $17.00', up from the previous 'approximately $16.25' guidance Raises FY 2025 consolidated revenues guidance to 'at least $128 billion' compared to the previous guidance range of $126 billion to $128 billion Affirms
Humana will release its 2Q25 financial results, as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on July 30, 2025. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. A webcast of the 2Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/. If you anticipate asking a question during the question-and-answer session, please register in advance using this link, https://register-conf.media-server.com/register/BIb5c00e1d1dc14cd7ad2b375d4f1cde21. Upon registration, telephone participants w
Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)
SC 13G/A - HUMANA INC (0000049071) (Subject)